Clinical Trial Detail

NCT ID NCT02520011
Title Alvocidib Biomarker-driven Phase 2 AML Study
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Tolero Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Alvocidib

Cytarabine + Mitoxantrone

Age Groups: adult

No variant requirements are available.